This information is intended for use by health professionals

1. Name of the medicinal product

Nimenrix powder and solvent for solution for injection in pre-filled syringe

Nimenrix powder and solvent for solution for injection in vials

Meningococcal groups A, C, W-135 and Y conjugate vaccine

2. Qualitative and quantitative composition

After reconstitution, 1 dose (0.5 ml) contains:

Neisseria meningitidis group A polysaccharide1

Neisseria meningitidis group C polysaccharide1

Neisseria meningitidis group W-135 polysaccharide1

Neisseria meningitidis group Y polysaccharide1

1conjugated to tetanus toxoid carrier protein

5 micrograms

5 micrograms

5 micrograms

5 micrograms

44 micrograms

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Powder and solvent for solution for injection.

The powder or cake is white.

The solvent is clear and colourless.

4. Clinical particulars
4.1 Therapeutic indications

Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by Neisseria meningitidis groups A, C, W-135, and Y.

4.2 Posology and method of administration

Posology

Nimenrix should be used in accordance with available official recommendations.

Primary immunisation

Infants from 6 weeks to less than 6 months of age: two doses, each of 0.5 ml, should be administered with an interval of 2 months between doses.

Infants from 6 months of age, children, adolescents and adults: a single 0.5 mL dose should be administered.

An additional primary dose of Nimenrix may be considered appropriate for some individuals (see section 4.4).

Booster doses

After completion of the primary immunisation course in infants 6 weeks to less than 12 months of age, a booster dose should be given at 12 months of age with an interval of at least 2 months after the last Nimenrix vaccination (see section 5.1).

In previously vaccinated individuals 12 months of age and older, Nimenrix may be given as a booster dose if they have received primary vaccination with a conjugated or plain polysaccharide meningococcal vaccine (see sections 4.4 and 5.1).

Method of administration

Immunisation should be carried out by intramuscular injection only.

In infants, the recommended injection site is the anterolateral aspect of the thigh. In individuals from 1 year of age, the recommended injection site is the anterolateral aspect of the thigh or the deltoid muscle (see sections 4.4 and 4.5).

For instructions on reconstitution of the medicinal product before administration, see section 6.6.

4.3 Contraindications

Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Nimenrix should under no circumstances be administered intravascularly, intradermally or subcutaneously.

It is good clinical practice to precede vaccination by a review of the medical history (especially with regard to previous vaccination and possible occurrence of undesirable effects) and a clinical examination.

Appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine.

Intercurrent illness

Vaccination with Nimenrix should be postponed in subjects suffering from an acute severe febrile illness. The presence of a minor infection, such as a cold, should not result in the deferral of vaccination.

Syncope

Syncope (fainting) can occur following, or even before, any vaccination especially in adolescents as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints.

Thrombocytopenia and coagulation disorders

Nimenrix should be given with caution to individuals with thrombocytopenia or any coagulation disorder since bleeding may occur following an intramuscular administration to these subjects.

Immunodeficiency

It may be expected that in patients receiving immunosuppressive treatment or patients with immunodeficiency, an adequate immune response may not be elicited.

Persons with familial complement deficiencies (for example, C5 or C3 deficiencies) and persons receiving treatments that inhibit terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis groups A, C, W-135 and Y, even if they develop antibodies following vaccination with Nimenrix.

Protection against meningococcal disease

Nimenrix will only confer protection against Neisseria meningitidis groups A, C, W-135 and Y. The vaccine will not protect against any other Neisseria meningitidis groups.

A protective immune response may not be elicited in all vaccines.

Effect of prior vaccination with plain polysaccharide meningococcal vaccine

Subjects previously vaccinated with a plain polysaccharide meningococcal vaccine and vaccinated with Nimenrix 30 to 42 months later had lower Geometric Mean Titres (GMTs) measured with a serum bactericidal assay using rabbit complement (rSBA) than subjects who had not been vaccinated with any meningococcal vaccine in the preceding 10 years (see section 5.1). The clinical relevance of this observation is unknown.

Effect of pre-vaccination antibody to tetanus toxoid

The safety and immunogenicity of Nimenrix was evaluated when it was sequentially administered or co-administered with a vaccine containing, diphtheria and tetanus toxoids, acellular pertussis, inactivated polioviruses (1, 2 and 3), hepatitis B surface antigen and Haemophilus influenzae type b polyribosyl ribose phosphate conjugated to tetanus toxoid (DTaP-HBV-IPV/Hib) in the second year of life. The administration of Nimenrix one month after the DTaP-HBV-IPV/Hib vaccine resulted in lower rSBA GMTs against groups A, C and W-135 compared with co-administration (see section 4.5). The clinical relevance of this observation is unknown.

Immune response in infants aged 6 months to less than 12 months

A single dose administered at 6 months was associated with lower human complement serum bactericidal assay (hSBA) titres to groups W-135 and Y compared with three doses administered at 2, 4, and 6 months (see section 5.1). The clinical relevance of this observation is unknown. If an infant aged 6 months to less than 12 months is expected to be at particular risk of invasive meningococcal disease due to exposure to groups W-135 and/or Y, consideration may be given to administering a second primary dose of Nimenrix after an interval of 2 months.

Immune responses in toddlers aged 12-14 months

Toddlers aged 12-14 months had similar rSBA titres to groups A, C, W-135 and Y at one month after one dose of Nimenrix or at one month after two doses of Nimenrix given two months apart.

A single dose was associated with lower hSBA titres to groups W-135 and Y compared with two doses given two months apart. Similar responses to groups A and C were observed after one or two doses (see section 5.1). The clinical relevance of the findings is unknown. If a toddler is expected to be at particular risk of invasive meningococcal disease due to exposure to groups W-135 and/or Y, consideration may be given to administering a second dose of Nimenrix after an interval of 2 months. Regarding waning of antibody against group A or group C after a first dose of Nimenrix in children aged 12-23 months, see under Persistence of serum bactericidal antibody titres.

Persistence of serum bactericidal antibody titres

Following administration of Nimenrix there is a waning of serum bactericidal antibody titres against group A when using hSBA (see section 5.1). The clinical relevance of this observation is unknown. However, if an individual is expected to be at particular risk of exposure to group A and received a dose of Nimenrix more than approximately one year previously, consideration may be given to administering a booster dose.

A decline in antibody titres over time has been observed for groups A, C, W-135 and Y. The clinical relevance of this observation is unknown. A booster dose might be considered in individuals vaccinated at toddler age remaining at high risk of exposure to meningococcal disease caused by groups A, C, W-135 or Y (see section 5.1).

Effect of Nimenrix on anti-tetanus antibody concentrations

Although an increase of the anti-tetanus toxoid (TT) antibody concentrations was observed following vaccination with Nimenrix, Nimenrix does not substitute for tetanus immunisation.

Giving Nimenrix with or one month before a TT-containing vaccine in the second year of life does not impair the response to TT or significantly affect safety. No data are available beyond the age of 2 years.

4.5 Interaction with other medicinal products and other forms of interaction

In infants, Nimenrix can be given concomitantly with combined DTaP-HBV-IPV/Hib vaccines and with 10-valent pneumococcal conjugate vaccine.

From age 1 year and above, Nimenrix can be given concomitantly with any of the following vaccines: hepatitis A (HAV) and hepatitis B (HBV) vaccines, measles - mumps - rubella (MMR) vaccine, measles - mumps - rubella - varicella (MMRV) vaccine, 10-valent pneumococcal conjugate vaccine or unadjuvanted seasonal influenza vaccine.

In the second year of life, Nimenrix can also be given concomitantly with combined diphtheria - tetanus - acellular pertussis (DTaP) vaccines, including combination DTaP vaccines with hepatitis B, inactivated poliovirus or Haemophilus influenzae type b (HBV, IPV or Hib) such as DTaP-HBV-IPV/Hib vaccine, and 13-valent pneumococcal conjugate vaccine.

In individuals aged 9 to 25 years, Nimenrix can be given concomitantly with human papillomavirus bivalent [Type 16 and 18] vaccine, recombinant (HPV2).

Whenever possible, Nimenrix and a TT containing vaccine, such as DTaP-HBV-IPV/Hib vaccine, should be co-administered or Nimenrix should be administered at least one month before the TT containing vaccine.

One month after co-administration with a 10-valent pneumococcal conjugate vaccine, lower Geometric Mean antibody Concentrations (GMCs) and opsonophagocytic assay (OPA) antibody GMTs were observed for one pneumococcal serotype (18C conjugated to tetanus toxoid carrier protein). The clinical relevance of this observation is unknown. There was no impact of co-administration on immune responses to the other nine pneumococcal serotypes.

One month after co-administration with a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed (Tdap) in subjects aged 9 to 25 years, lower GMCs were observed to each pertussis antigen (pertussis toxoid [PT], filamentous haemagglutinin [FHA] and pertactin [PRN]). More than 98% of subjects had anti-PT, FHA or PRN concentrations above the assay cut-off thresholds. The clinical relevance of these observations is unknown. There was no impact of co-administration on immune responses to Nimenrix or the tetanus or diphtheria antigens included in Tdap.

If Nimenrix is to be given at the same time as another injectable vaccine, the vaccines should always be administered at different injection sites.

It may be expected that in patients receiving immunosuppressive treatment, an adequate response may not be elicited.

4.6 Fertility, pregnancy and lactation

Pregnancy

There is limited experience with use of Nimenrix in pregnant women.

Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryo/foetal development, parturition or post-natal development (see section 5.3).

Nimenrix should be used during pregnancy only when clearly needed, and the possible advantages outweigh the potential risks for the foetus.

Breast-feeding

It is unknown whether Nimenrix is excreted in human milk.

Nimenrix should only be used during breast-feeding when the possible advantages outweigh the potential risks.

Fertility

Animal studies do not indicate direct or indirect harmful effects with respect to fertility.

4.7 Effects on ability to drive and use machines

No studies on the effects of Nimenrix on the ability to drive and use machines have been performed.

However, some of the effects mentioned under section 4.8 “Undesirable effects” may affect the ability to drive or use machines.

4.8 Undesirable effects

Summary of the safety profile

The safety of Nimenrix presented in the table below is based on two clinical study datasets as follows:

• A pooled analysis of data from 9,621 subjects administered a single dose of Nimenrix. This total included 3,079 toddlers (12 months to 23 months), 909 children between 2 and 5 years of age, 990 children between 6 and 10 years of age, 2,317 adolescents (11 to 17 years) and 2,326 adults (18 to 55 years).

• Data from a study in infants aged 6 to 12 weeks at the time of the first dose (Study MenACWY-TT-083), 1,052 subjects received at least one dose of a primary series of 2 or 3 doses of Nimenrix and 1,008 received a booster dose at approximately 12 months of age.

Safety data have also been evaluated in a separate study, in which a single dose of Nimenrix was administered to 274 individuals aged 56 years and older.

Local and general adverse reactions

In the 6-12 weeks and in the 12-14 months age groups who received 2 doses of Nimenrix given 2 months apart, the first and second doses were associated with similar local and systemic reactogenicity.

The local and general adverse reaction profile of a booster dose of Nimenrix given to subjects from 12 months through 30 years of age after primary vaccination with Nimenrix or other conjugated or plain polysaccharide meningococcal vaccines, was similar to the local and general adverse reaction profile observed after primary vaccination with Nimenrix, except for gastrointestinal symptoms (including diarrhoea, vomiting, and nausea), which were very common among subjects 6 years of age and older.

Tabulated list of adverse reactions

Adverse reactions reported are listed according to the following frequency categories:

Very common:

Common:

Uncommon:

Rare:

Very rare:

(≥1/10)

(≥1/100 to <1/10)

(≥1/1,000 to <1/100)

(≥1/10,000 to <1/1,000)

(<1/10,000)

Not known (cannot be estimated from available data)

Table 1 shows the adverse reactions reported from the studies in subjects aged from 6 weeks up to 55 years of age and post-marketing experience. Adverse reactions reported in subjects aged >55 years were similar to those observed in younger adults.

Table 1: Tabulated summary of adverse reactions by system organ class

System Organ Class

Frequency

Adverse reactions

Metabolism and nutrition disorders

Very common

Appetite lost

Psychiatric disorders

Very common

Irritability

Uncommon

Insomnia

Crying

Nervous system disorders

Very common

Drowsiness

Headache

Uncommon

Hypoaesthesia

Dizziness

Gastrointestinal disorders

Common

Diarrhoea

Vomiting

Nausea*

Skin and subcutaneous tissue disorders

Uncommon

Pruritus

Rash**

Musculoskeletal and connective tissue disorders

Uncommon

Myalgia

Pain in extremity

General disorders and administration site conditions

Very common

Fever

Swelling at injection site

Pain at injection site

Redness at injection site

Fatigue

Common

Injection site haematoma*

Uncommon

Malaise

Injection site induration

Injection site pruritus

Injection site warmth

Injection site anaesthesia

Not known***

Extensive limb swelling at the injection site, frequently associated with erythema, sometimes involving the adjacent joint or swelling of the entire injected limb

*Nausea and Injection site haematoma occurred at a frequency of Uncommon in infants

**Rash occurred at a frequency of Common in infants

***ADR identified post-marketing

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

United Kingdom

Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Ireland

Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: [email protected]

4.9 Overdose

No case of overdose has been reported.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: vaccines, meningococcal vaccines, ATC code: J07AH08

Mechanism of action

Anti-capsular meningococcal antibodies protect against meningococcal disease via complement mediated bactericidal activity. Nimenrix induces the production of bactericidal antibodies against capsular polysaccharides of Neisseria meningitidis groups A, C, W-135 and Y when measured by assays using either rSBA or hSBA.

Immunogenicity in infants

In Study MenACWY-TT-083, the first dose was administered at 6 to 12 weeks of age, the second after an interval of 2 months, and a third (booster) dose administered at approximately 12 months of age. DTaP-HBV-IPV/Hib and a 10-valent pneumococcal vaccine were co-administered. Nimenrix elicited rSBA and hSBA titres against the four meningococcal groups as shown in Table 2. The response against group C was non-inferior to the one elicited by licensed MenC-CRM and MenC-TT vaccines in terms of percentages with rSBA titres ≥8 at 1 month after the second dose.

Data from this study support the extrapolation of the immunogenicity data and posology to infants from 12 weeks to less than 6 months of age.

Table 2: rSBA and hSBA titres following two doses of Nimenrix (or MenC-CRM or MenC-TT) given 2 months apart with the first dose administered to infants 6-12 weeks of age and following a booster at 12 months of age (Study MenACWY-TT-083)

Meningo-coccal group

Vaccine group

Time point

rSBA*

hSBA**

N

≥8

GMT

N

≥8

GMT

(95% CI)

(95% CI)

(95% CI)

(95% CI)

A

Nimenrix

Post- dose 2(1)

456

97.4%

(95.4; 98.6)

203

(182; 227)

202

96.5%

(93.0; 98.6)

157

(131; 188)

Post-booster(1)

462

99.6%

(98.4; 99.9)

1561

(1412; 1725)

214

99.5%

(97.4;100)

1007

(836;1214)

C

Nimenrix

Post- dose 2(1)

456

98.7%

(97.2; 99.5)

612

(540; 693)

218

98.6%

(96.0; 99.7)

1308

(1052; 1627)

Post-booster(1)

463

99.8%

(98.8; 100)

1177

(1059; 1308)

221

99.5%

(97.5; 100)

4992

(4086; 6100)

MenC-CRM vaccine

Post- dose 2(1)

455

99.6%

(98.4; 99.9)

958

(850; 1079)

202

100%

(98.2; 100)

3188

(2646; 3841)

Post-booster(1)

446

98.4%

(96.8; 99.4)

1051

(920; 1202)

216

100%

(98.3; 100)

5438

(4412; 6702)

MenC-TT vaccine

Post- dose 2(1)

457

100%

(99.2; 100)

1188

(1080; 1307)

226

100%

(98.4; 100)

2626

(2219; 3109)

Post-booster(1)

459

100%

(99.2; 100)

1960

(1776; 2163)

219

100%

(98.3; 100)

5542

(4765; 6446)

W

Nimenrix

Post- dose 2(1)

455

99.1%

(97.8; 99.8)

1605

(1383; 1862)

217

100%

(98.3; 100)

753

(644; 882)

Post-booster(1)

462

99.8%

(98.8; 100)

2777

(2485; 3104)

218

100%

(98.3; 100)

5123

(4504; 5826)

Y

Nimenrix

Post- dose 2(1)

456

98.2%

(96.6; 99.2)

483

(419; 558)

214

97.7%

(94.6; 99.2)

328

(276; 390)

Post-booster(1)

462

99.4%

(99.1; 99.9)

881

(787; 986)

217

100%

(98.3; 100)

2954

(2498; 3493)

The analysis of immunogenicity was conducted on the primary according-to-protocol (ATP) cohort.

*rSBA analysis performed at Public Health England (PHE) laboratories in UK

**hSBA analysis performed at GSK laboratories

(1) blood sampling performed 21 to 48 days post vaccination

In Study MenACWY-TT-087, infants received either a single primary dose at 6 months followed by a booster dose at 15-18 months (DTaP-IPV/Hib and 10-valent pneumococcal conjugate vaccine was co-administered at both vaccination time points) or three primary doses at 2, 4, and 6 months followed by a booster dose at 15-18 months. A single primary dose administered at 6 months of age elicited robust rSBA titres to the four meningococcal groups, as measured by the percentage of subjects with rSBA titres ≥8, that were comparable to responses after the last dose of a three-dose primary series. A booster dose produced robust responses, comparable between the two dosing groups, against all four meningococcal groups. Results are shown in Table 3.

Table 3: rSBA and hSBA titres following a single dose of Nimenrix in infants at 6 months of age and pre-and post-booster at 15-18 months of age (Study MenACWY-TT-087)

Meningo-coccal group

Time point

rSBA*

hSBA**

N

≥8

(95% CI)

GMT

(95% CI)

N

≥8

(95% CI)

GMT

(95% CI)

A

Post-dose 1(1)

163

98.8%

(95.6; 99.9)

1333

(1035; 1716)

59

98.3%

(90.9; 100)

271

(206; 355)

Pre-booster

131

81.7%

(74; 87.9)

125

(84.4; 186)

71

66.2%

(54; 77)

20.8

(13.5; 32.2)

Post-booster(1)

139

99.3%

(96.1; 100)

2762

(2310; 3303)

83

100%

(95.7; 100)

1416

(1140; 1758)

C

Post-dose 1(1)

163

99.4%

(96.6; 100)

592

(482; 726)

66

100%

(94.6;100)

523

(382; 717)

Pre-booster

131

65.6%

(56.9; 73.7)

27.4

(20.6; 36.6)

78

96.2%

(89.2; 99.2)

151

(109; 210)

Post-booster(1)

139

99.%

(96.1; 100)

2525

(2102; 3033)

92

100%

(96.1; 100)

13360

(10953; 16296)

W

Post-dose 1(1)

163

93.9%

(89; 97)

1256

(917; 1720)

47

87.2%

(74.3; 95.2)

137

(78.4; 238)

Pre-booster

131

77.9%

(69.8; 84.6)

63.3

(45.6; 87.9)

53

100%

(93.3; 100)

429

(328; 559)

Post-booster(1)

139

100%

(97.4; 100)

3145

(2637; 3750)

59

100%

(93.9; 100)

9016

(7045; 11537)

Y

Post-dose 1(1)

163

98.8%

(95.6; 99.9)

1470

(1187; 1821)

52

92.3%

(81.5; 97.9)

195

(118; 323)

Pre-booster

131

88.5%

(81.8; 93.4)

106

(76.4; 148.1)

61

98.4%

(91.2; 100)

389

(292; 518)

Post-booster(1)

139

100%

(97.4; 100)

2749

(2301; 3283)

69

100%

(94.8; 100)

5978

(4747; 7528)

The analysis of immunogenicity was conducted on the primary according-to-protocol (ATP) cohort.

*rSBA analysis performed at Public Health England (PHE) laboratories in UK

**hSBA analysis performed at Neomed in Canada

(1) blood sampling performed 1 month post vaccination

Measurement of hSBA titres was a secondary endpoint in Study MenACWY-TT-087. Although similar responses to groups A and C were observed with both dosing schedules, a single primary dose in infants at 6 months was associated with lower hSBA titres to groups W-135 and Y as measured by the percentage of subjects with hSBA titres ≥8 [87.2% (95% CI: 74.3, 95.2) and 92.3% (95% CI: 81.5, 97.9), respectively] compared with three primary doses at 2, 4, and 6 months of age [100% (95% CI: 96.6, 100) and 100% (95% CI: 97.1, 100), respectively] (see section 4.4). After a booster dose, the hSBA titres to all four meningococcal groups were comparable between the two dosing schedules. Results are shown in Table 3.

Immunogenicity in toddlers aged 12-23 months

In clinical studies MenACWY-TT-039 and MenACWY-TT-040, a single dose of Nimenrix elicited SBA titres against the four meningococcal groups, with group C rSBA titres that were comparable to those elicited by a licensed MenC-CRM vaccine in terms of the percentages of subjects with rSBA titres ≥8. In Study MenACWY-TT-039, hSBA was also measured as a secondary endpoint. Results are shown in Table 4.

Table 4: SBA* titres following a single dose of Nimenrix (or MenC-CRM) in toddlers aged 12-23 months (Studies MenACWY-TT-039/040)

Meningo-coccal group

Vaccine group

Study MenACWY-TT-039(1)

Study MenACWY-TT-040(2)

rSBA*

hSBA*

rSBA*

N

≥8

(95% CI)

GMT

(95% CI)

N

≥8

(95% CI)

GMT

(95% CI)

N

≥8

(95% CI)

GMT

(95% CI)

A

Nimenrix

354

99.7%

(98.4; 100)

2205

(2008; 2422)

338

77.2%

(72.4; 81.6)

19.0

(16.4; 22.1)

183

98.4%

(95.3; 99.7)

3170

(2577; 3899)

C

Nimenrix

354

99.7%

(98.4; 100)

478

(437; 522)

341

98.5%

(96.6; 99.5)

196

(175; 219)

183

97.3%

(93.7; 99.1)

829

(672; 1021)

MenC-CRM vaccine

121

97.5%

(92.9; 99.5)

212

(170; 265)

116

81.9%

(73.7; 88.4)

40.3

(29.5; 55.1)

114

98.2%

(93.8; 99.8)

691

(521; 918)

W-135

Nimenrix

354

100%

(99.0; 100)

2682

(2453; 2932)

336

87.5%

(83.5 ; 90.8)

48.9

(41.2; 58.0)

186

98.4%

(95.4; 99.7)

4022

(3269; 4949)

Y

Nimenrix

354

100%

(99.0; 100)

2729

(2473; 3013)

329

79.3%

(74.5; 83.6)

30.9

(25.8; 37.1)

185

97.3%

(93.8; 99.1)

3168

(2522; 3979)

The analysis of immunogenicity was conducted on the ATP cohorts.

(1) blood sampling performed 42 to 56 days post vaccination

(2) blood sampling performed 30 to 42 days post vaccination

* SBA analyses performed at GSK laboratories

In Study Men ACWY-TT-104, Nimenrix elicited rSBA titres against all four meningococcal groups following one or two doses administered 2 months apart that were similar in terms of the percentage of subjects with rSBA titre ≥8 and GMT as shown in Table 5.

Table 5: rSBA and hSBA titres following one or two doses of Nimenrix with the first dose administered to toddlers aged 12-14 months ( Study MenACWY-TT-104)

Meningo-coccal group

Nimenrix dose group

Time point(1)

rSBA*

hSBA**

N

≥8

(95% CI)

GMT

(95% CI)

N

≥8

(95% CI)

GMT

(95% CI)

A

1 dose

Post dose 1

180

97.8%

(94.4; 99.4)

1437

(1118; 1847)

74

95.9%

(88.6, 99.2)

118

(86.8; 161)

2 doses

Post dose 1

158

96.8%

(92.8; 99.0)

1275

(970; 1675)

66

97.0%

(89.5; 99.6)

133

(98.1; 180)

Post dose 2

150

98.0%

(94.3; 99.6)

1176

(922; 1501)

66

97.0%

(89.5; 99.6)

170

(126; 230)

C

1 dose

Post dose 1

179

95.0%

(90.7; 97.7)

452

(346; 592)

78

98.7%

(93.1; 100)

152

(105; 220)

2 doses

Post dose 1

157

95.5%

(91.0; 98.2)

369

(281; 485)

70

95.7%

(88.0; 99.1)

161

(110; 236)

Post dose 2

150

98.7%

(95.3; 99.8)

639

(522; 783)

69

100%

(94.8; 100)

1753

(1278; 2404)

W-135

1 dose

Post dose 1

180

95.0%

(90.8; 97.7)

2120

(1601; 2808)

72

62.5%

(50.3; 73.6)

27.5

(16.1; 46.8)

2 doses

Post dose 1

158

94.9%

(90.3; 97.8)

2030

(1511; 2728)

61

68.9%

(55.7; 80.1)

26.2

(16.0; 43.0)

Post dose 2

150

100%

(97.6; 100)

3533

(2914; 4283)

70

97.1%

(90.1; 99.7)

757

(550; 1041)

Y

1 dose

Post dose 1

180

92.8%

(88.0; 96.1)

952

(705; 1285)

71

67.6%

(55.5; 78.2)

41.2

(23.7; 71.5)

2 doses

Post dose 1

157

93.6%

(88.6; 96.9)

933

(692; 1258)

56

64.3%

(50.4; 76.6)

31.9

(17.6; 57.9)

Post dose 2

150

99.3%

(96.3; 100)

1134

(944; 1360)

64

95.3%

(86.9; 99.0)

513

(339; 775)

The analysis of immunogenicity was conducted on the according-to-protocol (ATP) cohort

(1) blood sampling performed 21-48 days post vaccination

* rSBA analysis performed at PHE laboratories

**hSBA analysis performed at GSK laboratories

In Study MenACWY-TT-104, hSBA titres were measured as a secondary endpoint. Nimenrix elicited hSBA titres against groups W-135 and Y that were higher in terms of the percentage of subjects with hSBA titre ≥8 when two doses were given compared with one (see section 4.4). Nimenrix elicited hSBA titres against groups A and C that were similar in terms of the percentage of subjects with hSBA titre ≥8 when two doses were given compared with one. Results are shown in Table 5.

rSBA and hSBA titres were determined over a period of 10 years in children initially vaccinated with one dose of Nimenrix or MenC-CRM at 12 to 23 months of age in study MenACWY-TT-027. Persistence of SBA titres was evaluated in two extension studies: MenACWY-TT-032 (up to 5 years) and MenACWY-TT-100 (up to 10 years). Study MenACWY-TT-100 also evaluated the response to a single booster dose of Nimenrix administered 10 years following the initial vaccination with Nimenrix or MenC-CRM. Results are shown in Table 6 (see section 4.4).

Table 6: rSBA and hSBA titres following a single dose of Nimenrix (or MenC-CRM) in toddlers aged 12-23 months, persistence up to 10 years, and post-booster administered 10 years following initial vaccination (Studies MenACWY-TT-027/032/100)

Meningo-coccal group

Vaccine group

Time point

rSBA*

hSBA**

N

≥8

(95% CI)

GMT

(95% CI)

N

≥8

(95% CI)

GMT

(95% CI)

A

Nimenrix

Month 1(1)

222

100%

(98.4; 100)

3707

(3327; 4129)

217

91.2%

(86.7; 94.6)

59.0

(49.3; 70.6)

Year 4(2)

45

64.4%

(48.8; 78.1)

35.1

(19.4; 63.4)

44

52.3%

(36.7; 67.5)

8.8

(5.4; 14.2)

Year 5(2)

49

73.5%

(58.9; 85.1)

37.4

(22.1; 63.2)

45

35.6%

(21.9: 51.2)

5.2

(3.4; 7.8)

Year 10(3)

(Pre-booster)

62

66.1%

(53.0; 77.7)

28.9

(16.4; 51.0)

59

25.4%

(15.0; 38.4)

4.2

(3.0; 5.9)

(Post-booster)(3,4)

62

98.4%

(91.3; 100)

5122

(3726; 7043)

62

100%

(94.2; 100)

1534

(1112; 2117)

C

Nimenrix

Month 1(1)

220

100%

(98.3; 100)

879

(779; 991)

221

99.1%

(96.8; 99.9)

190

(165; 219)

Year 4(2)

45

97.8%

(88.2; 99.9)

110

(62.7; 192)

45

97.8%

(88.2; 99.9)

370

(214; 640)

Year 5(2)

49

77.6%

(63.4; 88.2)

48.9

(28.5; 84.0)

48

91.7%

(80.0; 97.7)

216

(124; 379)

Year 10(3)

(Pre-booster)

62

82.3%

(70.5; 90.8)

128

(71.1; 231)

60

91.7%

(81.6; 97.2)

349

(197; 619)

(Post-booster)(3,4)

62

100%

(94.2; 100)

7164

(5478; 9368)

59

100%

(93.9; 100)

33960

(23890; 48274)

MenC-CRM vaccine

Month 1(1)

68

98.5%

(92.1; 100)

415

(297; 580)

68

72.1%

(59.9; 82.3)

21.2

(13.9; 32.3)

Year 4(2)

10

80.0%

(44.4; 97.5)

137

(22.6; 832)

10

70.0%

(34.8; 93.3)

91.9

(9.8; 859)

Year 5(2)

11

63.6%

(30.8; 89.1)

26.5

(6.5; 107)

11

90.9%

(58.7; 99.8)

109

(21.2; 557)

Year 10(3)

(Pre-booster)

16

87.5%

(61.7; 98.4)

86.7

(29.0; 259)

15

93.3%

(68.1; 99.8)

117

(40.0; 344)

(Post-booster)(3,4)

16

100%

(79.4; 100)

5793

(3631; 9242)

15

100%

(78.2; 100)

42559

(20106; 90086)

W-135

Nimenrix

Month 1(1)

222

100%

(98.4; 100)

5395

(4870; 5976)

177

79.7%

(73.0; 85.3)

38.8

(29.7; 50.6)

Year 4(2)

45

60.0%

(44.3; 74.3)

50.8

(24.0; 108)

45

84.4%

(70.5; 93.5)

76.9

(44.0; 134)

Year 5(2)

49

34.7%

(21.7; 49.6)

18.2

(9.3; 35.3)

46

82.6%

(68.6; 92.2)

59.7

(35.1; 101)

Year 10(3)

(Pre-booster)

62

30.6%

(19.6; 43.7)

15.8

(9.1; 27.6)

52

44.2%

(30.5; 58.7)

7.7

(4.9; 12.2)

(Post-booster)(3,4)

62

100%

(94.2; 100)

25911

(19120; 35115)

62

100%

(94.2; 100)

11925

(8716; 16316)

Y

Nimenrix

Month 1(1)

222

100%

(98.4; 100)

2824

(2529; 3153)

201

66.7%

(59.7; 73.1)

24.4

(18.6; 32.1)

Year 4(2)

45

62.2%

(46.5; 76.2)

44.9

(22.6; 89.3)

41

87.8%

(73.8; 95.9)

74.6

(44.5; 125)

Year 5(2)

49

42.9%

(28.8; 57.8)

20.6

(10.9; 39.2)

45

80.0%

(65.4; 90.4)

70.6

(38.7; 129)

Year 10(3)

(Pre-booster)

62

45.2%

(32.5; 58.3)

27.4

(14.7; 51.0)

56

42.9%

(29.7; 56.8)

9.1

(5.5; 15.1)

(Post-booster)(3,4)

62

98.4%

(91.3; 100)

7661

(5263; 11150)

61

100%

(94.1; 100)

12154

(9661; 15291)

The analysis of immunogenicity was conducted on the ATP cohorts for 1 month and 5 years post vaccination and the booster ATP cohort. Subjects with a suboptimal response to meningococcal group C (defined as SBA titre below the pre-defined assay cut-off) were to receive an additional dose of MenC vaccine before Year 6. These subjects were excluded from the analysis at Years 4 and 5 but included in the analysis at Year 10.

(1) Study MenACWY-TT-027

(2) Study MenACWY-TT-032

(3) Study MenACWY-TT-100

(4) Blood sampling was performed 1 month after a booster dose at Year 10.

*rSBA analysis performed at GSK laboratories for 1 month post primary vaccination samples and at PHE laboratories in UK for subsequent sampling time points.

** hSBA analysis performed at GSK laboratories and at Neomed in Canada for time points in MenACWY-TT-100.

Persistence of booster response

Study MenACWY-TT-102 evaluated the persistence of SBA titres up to 6 years after a booster dose of Nimenrix or MenC-CRM197 administered in Study MenACWY-TT-048 to children who initially received the same vaccine at 12 to 23 months of age in Study MenACWY-TT-039. A single booster dose was administered 4 years after the initial vaccination. Results are shown in Table 7 (see section 4.4).

Table 7: rSBA and hSBA titres following a single dose of Nimenrix (or MenC-CRM) in toddlers aged 12-23 months, persistence at 4 years and response following a booster 4 years after initial vaccination, and persistence up to 6 years following booster vaccination (Studies MenACWY-TT-039/048/102)

Meningo-coccal group

Vaccine group

Time point

rSBA*

hSBA**

N

≥8

(95% CI)

GMT

(95% CI)

N

≥8

(95% CI)

GMT

(95% CI)

A

Nimenrix

Month 1(1)

354

99.7%

(98.4; 100)

2205

(2008; 2422)

338

77.2%

(72.4; 81.6)

19.0

(16.4; 22.1)

Year 4(2)

(Pre-Nimenrix booster)

212

74.5%

(68.1; 80.2)

112

(80.3; 156)

187

28.9%

(22.5; 35.9)

4.8

(3.9; 5.9)

(Post-booster)(2,3)

214

100%

(98.3; 100)

7173

(6389; 8054)

202

99.5%

(97.3; 100)

1343

(1119; 1612)

5 years after booster dose(4)

137

89.8%

(83.4; 94.3)

229

(163; 322)

135

53.3%

(44.6; 62.0)

13.2

(9.6; 18.3)

6 years after booster dose(4)

134

92.5%

(86.7; 96.4)

297

(214; 413)

130

58.5%

(49.5; 67.0)

14.4

(10.5; 19.7)

C

Nimenrix

Month 1(1)

354

99.7%

(98.4; 100)

478

(437; 522)

341

98.5%

(96.6; 99.5)

196

(175; 219)

Year 4(2)

(Pre-Nimenrix booster)

213

39.9%

(33.3; 46.8)

12.1

(9.6; 15.2)

200

73.0%

(66.3; 79.0)

31.2

(23.0; 42.2)

(Post-booster)(2,3)

215

100%

(98.3; 100)

4512

(3936; 5172)

209

100%

(98.3; 100)

15831

(13626; 18394)

5 years after booster dose(4)

137

80.3%

(72.6; 86.6)

66.0

(48.1; 90.5)

136

99.3%

(96.0; 100)

337

(261; 435)

6 years after booster dose(4)

134

71.6%

(63.2; 79.1)

39.6

(28.6; 54.6)

130

97.7%

(93.4; 99.5)

259

(195; 345)

MenC-CRM vaccine

Month 1(1)

121

97.5%

(92.9; 99.5)

212

(170; 265)

116

81.9%

(73.7; 88.4)

40.3

(29.5; 55.1)

Year 4(2)

(Pre-MenC-CRM197 booster)

43

37.2%

(23.0; 53.3)

14.3

(7.7; 26.5)

31

48.4%

(30.2; 66.9)

11.9

(5.1; 27.6)

(Post-booster)(2,3)

43

100%

(91.8; 100)

3718

(2596; 5326)

33

100%

(89.4; 100)

8646

(5887; 12699)

5 years after booster dose(4)

23

78.3%

(56.3; 92.5)

47.3

(19.0; 118)

23

100%

(85.2; 100)

241

(139; 420)

6 years after booster dose(4)

23

65.2%

(42.7; 83.6)

33.0

(14.7; 74.2)

23

95.7%

(78.1; 99.9)

169

(94.1; 305)

W-135

Nimenrix

Month 1(1)

354

100%

(99.0; 100)

2682

(2453; 2932)

336

87.5%

(83.5; 90.8)

48.9

(41.2; 58.0)

Year 4(2)

(Pre-Nimenrix booster)

213

48.8%

(41.9; 55.7)

30.2

(21.9; 41.5)

158

81.6%

(74.7; 87.3)

48.3

(36.5; 63.9)

(Post-booster)(2,3)

215

100%

(98.3; 100)

10950

(9531; 12579)

192

100%

(98.1; 100)

14411

(12972 ; 16010)

5 years after booster dose(4)

137

88.3%

(81.7; 93.2)

184

(130; 261)

136

100%

(97.3; 100)

327

(276; 388)

6 years after booster dose(4)

134

85.8%

(78.7; 91.2)

172

(118; 251)

133

98.5%

(94.7; 99.8)

314

(255; 388)

Y

Nimenrix

Month 1(1)

354

100%

(99.0; 100)

2729

(2473; 3013)

329

79.3%

(74.5; 83.6)

30.9

(25.8; 37.1)

Year 4(2)

(Pre-Nimenrix booster)

213

58.2%

(51.3; 64.9)

37.3

(27.6; 50.4)

123

65.9%

(56.8; 74.2)

30.2

(20.2; 45.0)

(Post-booster)(2,3)

215

100%

(98.3; 100)

4585

(4129; 5093)

173

100%

(97.9; 100)

6776

(5961; 7701)

5 years after booster dose(4)

137

92.7%

(87.0; 96.4)

265

(191; 368)

137

97.8%

(93.7; 99.5)

399

(321; 495)

6 years after booster dose(4)

134

94.0%

(88.6; 97.4)

260

(189; 359)

131

97.7%

(93.5; 99.5)

316

(253; 394)

The analysis of immunogenicity was conducted on the ATP cohorts for each time point.

(1) Study MenACWY-TT-039

(2) Study MenACWY-TT-048

(3) Blood sampling was performed 1 month after a booster dose at Year 4.

(4) Study MenACWY-TT-102

*rSBA analysis performed at GSK laboratories for 1 month post primary vaccination samples and at PHE laboratories in UK for subsequent sampling time points.

** hSBA analysis performed at GSK laboratories and at Neomed in Canada for time points in MenACWY-TT-102.

Immunogenicity in children aged 2-10 years

In Study MenACWY-TT-081, a single dose of Nimenrix was demonstrated to be non-inferior to another licensed MenC-CRM vaccine in terms of vaccine response to group C [94.8% (95% CI: 91.4; 97.1) and 95.7% (95% CI: 89.2; 98.8) respectively]. The GMT was lower for the Nimenrix group [2795 (95% CI: 2393; 3263)] versus the MenC-CRM vaccine [5292 (95% CI: 3815; 7340)].

In Study MenACWY-TT-038, a single dose of Nimenrix was demonstrated to be non-inferior to the licensed ACWY-PS vaccine in terms of vaccine response to the four meningococcal groups as shown in Table 8.

Table 8: rSBA* titres following a single dose of Nimenrix (or ACWY-PS) in children aged 2-10 years (Study MenACWY-TT-038)

Meningo-coccal group

Nimenrix (1)

ACWY-PS vaccine (1)

N

VR

(95% CI)

GMT

(95% CI)

N

VR

(95% CI)

GMT

(95% CI)

A

594

89.1%

(86.3; 91.5)

6343

(5998; 6708)

192

64.6%

(57.4; 71.3)

2283

(2023; 2577)

C

691

96.1%

(94.4; 97.4)

4813

(4342; 5335)

234

89.7%

(85.1; 93.3)

1317

(1043; 1663)

W-135

691

97.4%

(95.9; 98.4)

11543

(10873; 12255)

236

82.6%

(77.2; 87.2)

2158

(1815; 2565)

Y

723

92.7%

(90.5; 94.5)

10825

(10233; 11452)

240

68.8%

(62.5; 74.6)

2613

(2237; 3052)

The analysis of immunogenicity was conducted on the ATP cohort.

(1) Blood sampling performed 1 month post vaccination

VR: vaccine response defined as the proportion of subjects with:

• rSBA titres ≥32 for initially seronegative subjects (i.e., pre-vaccination rSBA titre <8)

• at least a 4-fold increase in rSBA titres from pre- to post-vaccination for initially seropositive subjects (i.e., pre-vaccination rSBA titre ≥8)

* rSBA analysis performed at GSK laboratories

Persistence of SBA titres was evaluated in children initially vaccinated in Study MenACWY-TT-081 as shown in Table 9 (see section 4.4).

Table 9: rSBA and hSBA titres up to 44 months following Nimenrix (or MenC-CRM) in children aged 2-10 years at time of vaccination (Study MenACWY-TT-088)

Meningo-coccal group

Vaccine group

Time-point

(months)

rSBA*

hSBA**

N

≥8

(95% CI)

GMT

(95% CI)

N

≥8

(95% CI)

GMT

(95% CI)

A

Nimenrix

32

193

86.5%

(80.9; 91.0)

196

(144; 267)

90

25.6%

(16.9; 35.8)

4.6

(3.3; 6.3)

44

189

85.7%

(79.9; 90.4)

307

(224; 423)

89

25.8%

(17.1; 36.2)

4.8

(3.4; 6.7)

C

Nimenrix

32

192

64.6%

(57.4; 71.3)

34.8

(26.0; 46.4)

90

95.6%

(89.0; 98.8)

75.9

(53.4; 108)

44

189

37.0%

(30.1; 44.3)

14.5

(10.9; 19.2)

82

76.8%

(66.2; 85.4)

36.4

(23.1; 57.2)

MenC-CRM vaccine

32

69

76.8%

(65.1; 86.1)

86.5

(47.3; 158)

33

90.9%

(75.7; 98.1)

82.2

(34.6; 196)

44

66

45.5%

(33.1; 58.2)

31.0

(16.6; 58.0)

31

64.5%

(45.4; 80.8)

38.8

(13.3; 113)

W-135

Nimenrix

32

193

77.2%

(70.6; 82.9)

214

(149; 307)

86

84.9%

(75.5; 91.7)

69.9

(48.2; 101)

44

189

68.3%

(61.1; 74.8)

103

(72.5; 148)

87

80.5%

(70.6; 88.2)

64.3

(42.7; 96.8)

Y

Nimenrix

32

193

81.3%

(75.1; 86.6)

227

(165; 314)

91

81.3%

(71.8; 88.7)

79.2

(52.5; 119)

44

189

62.4%

(55.1; 69.4)

78.9

(54.6; 114)

76

82.9%

(72.5; 90.6)

127

(78.0; 206)

The analysis of immunogenicity was conducted on the ATP cohort for persistence adapted for each time-point.

*rSBA analysis performed at PHE laboratories in UK

** hSBA analysis performed at GSK laboratories

Persistence of hSBA titres was evaluated 1 year after vaccination in children aged 6-10 years who were initially vaccinated in Study MenACWY-TT-027 (Table 10) (see section 4.4).

Table 10: hSBA* titres following a single dose of Nimenrix (or ACWY-PS) in children aged 6-10 years and persistence 1 year following vaccination (Studies MenACWY-TT-027/028)

Meningo-coccal group

Vaccine group

1 month post-vaccination

(Study MenACWY-TT-027)

1 year persistence

(Study MenACWY-TT-028)

N

≥8

(95% CI)

GMT

(95% CI)

N

≥8

(95% CI)

GMT

(95% CI)

A

Nimenrix

105

80.0 %

(71.1; 87.2)

53.4

(37.3; 76.2)

104

16.3%

(9.8; 24.9)

3.5

(2.7; 4.4)

ACWY-PS vaccine

35

25.7%

(12.5;43.3)

4.1

(2.6;6.5)

35

5.7%

(0.7;19.2)

2.5

(1.9;3.3)

C

Nimenrix

101

89.1%

(81.3;94.4)

156

(99.3;244)

105

95.2%

(89.2;98.4)

129

(95.4;176)

ACWY-PS vaccine

38

39.5%

(24.0;56.6)

13.1

(5.4;32.0)

31

32.3%

(16.7;51.4)

7.7

(3.5;17.3)

W-135

Nimenrix

103

95.1%

(89.0;98.4)

133

(99.9;178)

103

100%

(96.5;100)

257

(218;302)

ACWY-PS vaccine

35

34.3%

(19.1;52.2)

5.8

(3.3;9.9)

31

12.9%

(3.6;29.8)

3.4

(2.0;5.8)

Y

Nimenrix

89

83.1%

(73.7;90.2)

95.1

(62.4;145)

106

99.1%

(94.9;100)

265

(213;330)

ACWY-PS vaccine

32

43.8%

(26.4;62.3)

12.5

(5.6;27.7)

36

33.3%

(18.6;51.0)

9.3

(4.3;19.9)

The analysis of immunogenicity was conducted on the ATP cohort for persistence at Year 1.

hSBA analysis was not performed for children aged 2 to <6 years (at time of vaccination).

* hSBA analysis performed at GSK laboratories

SBA titres were determined over a period of 10 years in children initially vaccinated with one dose of Nimenrix or ACWY-PS at 2 to 10 years of age in Study MenACWY-TT-027. Persistence of SBA titres was evaluated in two extension studies: MenACWY-TT-032 (up to 5 years) and MenACWY-TT-100 (up to 10 years). Study MenACWY-TT-100 also evaluated the response to a single booster dose of Nimenrix administered 10 years following the initial vaccination with Nimenrix or ACWY-PS. Results are shown in Table 11 (see section 4.4).

Table 11: rSBA and hSBA titres following a single dose of Nimenrix (or ACWY-PS) in children aged 2-10 years, persistence up to 10 years, and post-booster administered 10 years following initial vaccination (Studies MenACWY-TT-027/032/100)

Meningo-coccal group

Vaccine group

Time point

rSBA*

hSBA**

N

≥8

(95% CI)

GMT

(95% CI)

N

≥8

(95% CI)

GMT

(95% CI)

A

Nimenrix

Month 1(1)

225

100%

(98.4; 100)

7301

(6586; 8093)

111(5)

81.1%

(72.5; 87.9)

57.0

(40.3; 80.6)

Year 5(2)

98

90.8%

(83.3; 95.7)

141

(98.2; 203)

n/a(6)

--

--

Year 6(3)

98

79.6%

(70.3; 87.1)

107

(66.0; 174)

90

41.1%

(30.8; 52.0)

6.5

(4.8; 8.8)

Year 10(3)

(Pre-booster)

73

89.0%

(79.5; 95.1)

96.3

(57.1; 163)

62

33.9%

(22.3; 47.0)

4.5

(3.3; 6.2)

(Post-booster)(3,4)

74

95.9%

(88.6; 99.2)

4626

(3041; 7039)

73

100%

(95.1; 100)

1213

(994; 1481)

ACWY-PS

vaccine

Month 1(1)

75

100%

(95.2; 100)

2033

(1667; 2480)

35(5)

25.7%

(12.5; 43.3)

4.1

(2.6; 6.5)

Year 5(2)

13

15.4%

(1.9; 45.4)

4.7

(3.7; 6.0)

n/a(6)

--

--

Year 6(3)

24

12.5%

(2.7; 32.4)

5.8

(3.5; 9.6)

21

33.3%

(14.6; 57.0)

5.9

(3.0; 11.7)

Year 10(3)

(Pre-booster)

17

23.5%

(6.8; 49.9)

8.0

(3.3; 19.3)

17

29.4%

(10.3; 56.0)

6.2

(2.4; 15.7)

(Post-booster)(3,4)

17

100%

(80.5; 100)

6414

(3879; 10608)

17

100%

(80.5; 100)

211

(131; 340)

C

Nimenrix

Month 1(1)

225

100%

(98.4; 100)

2435

(2106; 2816)

107(5)

89.7%

(82.3; 94.8)

155

(101; 237)

Year 5(2)

98

90.8%

(83.3; 95.7)

79.7

(56.0; 113)

n/a(6)

--

--

Year 6(3)

98

82.7%

(73.7; 89.6)

193

(121; 308)

97

93.8%

(87.0; 97.7)

427

(261; 700)

Year 10(3)

(Pre-booster)

74

85.1%

(75.0; 92.3)

181

(106; 310)

73

91.8%

(83.0; 96.9)

222

(129; 380)

(Post-booster)(3,4)

74

100%

(95.1; 100)

4020

(3319; 4869)

71

100%

(94.9; 100)

15544

(11735; 20588)

ACWY-PS vaccine

Month 1(1)

74

100%

(95.1; 100)

750

(555; 1014)

38(5)

39.5%

(24.0; 56.6)

13.1

(5.4; 32.0)

Year 5(2)

13

100%

(75.3; 100)

128

(56.4; 291)

n/a(6)

--

--

Year 6(3)

24

79.2%

(57.8; 92.9)

98.7

(42.2; 231)

24

100%

(85.8; 100)

235

(122; 451)

Year 10(3)

(Pre-booster)

17

76.5%

(50.1; 93.2)

96.2

(28.9; 320)

17

100%

(80.5; 100)

99.1

(35.8; 274)

(Post-booster)(3,4)

17

100%

(80.5; 100)

15101

(7099; 32122)

17

94.1

(71.3; 99.9)

44794

(10112; 198440)

W-135

Nimenrix

Month 1(1)

225

100%

(98.4; 100)

11777

(10666; 13004)

107(5)

95.3%

(89.4; 98.5)

134

(101; 178)

Year 5(2)

98

78.6%

(69.1; 86.2)

209

(128; 340)

n/a(6)

--

--

Year 6(3)

98

73.5%

(63.6; 81.9)

265

(155; 454)

92

81.5%

(72.1; 88.9)

62.5

(42.0; 93.1)

Year 10(3)

(Pre-booster)

74

68.9%

(57.1; 79.2)

206

(109; 392)

59

61.0%

(47.4; 73.5)

17.5

(10.5; 29.2)

(Post-booster)(3,4)

74

100%

(95.1; 100)

27944

(22214; 35153)

74

100%

(95.1; 100)

6965

(5274; 9198)

ACWY-PS vaccine

Month 1(1)

75

100%

(95.2; 100)

2186

(1723; 2774)

35(5)

34.3%

(19.1; 52.2)

5.8

(3.3, 9.9)

Year 5(2)

13

0%

(0.0; 24.7)

4.0

(4.0; 4.0)

n/a(6)

--

--

Year 6(3)

24

12.5%

(2.7; 32.4)

7.6

(3.7; 15.6)

23

30.4%

(13.2; 52.9)

7.0

(2.9; 16.9)

Year 10(3)

(Pre-booster)

17

23.5%

(6.8; 49.9)

15.4

(4.2; 56.4)

15

26.7%

(7.8; 55.1)

4.1

(2.0; 8.5)

(Post-booster)(3,4)

17

94.1%

(71.3; 99.9)

10463

(3254; 33646)

15

100%

(78.2; 100)

200

(101; 395)

Y

Nimenrix

Month 1(1)

225

100%

(98.4; 100)

6641

(6044; 7297)

94(5)

83.0%

(73.8; 89.9)

93.7

(62.1; 141)

Year 5(2)

98

78.6%

(69.1; 86.2)

143

(88.0; 233)

n/a(6)

--

--

Year 6(3)

98

71.4%

(61.4; 80.1)

136

(82.6; 225)

89

65.2%

(54.3; 75.0)

40.3

(23.9; 68.1)

Year 10(3)

(Pre-booster)

74

67.6%

(55.7; 78.0)

98.5

(54.3; 179)

65

72.3%

(59.8; 82.7)

35.7

(21.0; 60.6)

(Post-booster)(3,4)

74

100%

(95.1; 100)

7530

(5828; 9729)

74

100%

(95.1; 100)

11127

(8909; 13898)

ACWY-PS vaccine

Month 1(1)

75

100%

(95.2; 100)

1410

(1086; 1831)

32(5)

43.8%

(26.4; 62.3)

12.5

(5.6; 27.7)

Year 5(2)

13

7.7%

(0.2; 36.0)

5.5

(2.7; 11.1)

n/a(6)

--

--

Year 6(3)

24

20.8%

(7.1; 42.2)

11.6

(4.7; 28.7)

24

25.0%

(9.8; 46.7)

7.3

(2.7; 19.8)

Year 10(3)

(Pre-booster)

17

17.6%

(3.8; 43.4)

10.2

(3.5; 30.2)

14

35.7%

(12.8; 64.9)

7.8

(2.5; 24.4)

(Post-booster)(3,4)

17

100%

(80.5; 100)

6959

(3637; 13317)

17

100%

(80.5; 100)

454

(215; 960)

The analysis of immunogenicity was conducted on the ATP cohort for each time point. Subjects with a suboptimal response to meningococcal group C (defined as SBA titre below the pre-defined assay cut-off) were to receive an additional dose of MenC vaccine before Year 6. These subjects were excluded from the analysis at Year 5 but included in the analyses at Years 6 and 10.

(1) Study MenACWY-TT-027

(2) Study MenACWY-TT-032

(3) Study MenACWY-TT-100

(4) Blood sampling was performed 1 month after a booster dose at Year 10.

(5) Includes children aged 6 to <11 years. hSBA analysis was not performed for children aged 2 to <6 years (at time of vaccination).

(6) Per the protocol for Study MenACWY-TT-032, hSBA was not measured for this age group at Year 5.

*rSBA analysis performed at GSK laboratories for 1 month post primary vaccination samples and at PHE laboratories in UK for subsequent sampling time points.

**hSBA analysis performed at GSK laboratories and at Neomed in Canada for time points in MenACWY-TT-100.

Immunogenicity in adolescents aged 11-17 years and adults aged ≥18 years

In two clinical studies, conducted in adolescents aged 11-17 years (Study MenACWY-TT-036) and in adults aged 18-55 years (Study MenACWY-TT-035), either one dose of Nimenrix or one dose of the ACWY-PS vaccine was administered.

Nimenrix was demonstrated to be immunologically non-inferior to the ACWY-PS vaccine in terms of vaccine response as shown in Table 12.

Table 12: rSBA* titres following a single dose of Nimenrix (or ACWY-PS) in adolescents aged 11-17 years and adults aged 18-55 years (Studies MenACWY-TT-035/036)

Meningo-coccal group

Vaccine group

Study MenACWY-TT-036

(11-17 years)(1)

Study MenACWY-TT-035

(18-55 years)(1)

N

VR

(95% CI)

GMT

(95% CI)

N

VR

(95% CI)

GMT

(95% CI)

A

Nimenrix

553

85.4%

(82.1; 88.2)

5928

(5557; 6324)

743

80.1%

(77.0; 82.9)

3625

(3372; 3897)

ACWY-PS vaccine

191

77.5%

(70.9; 83.2)

2947

(2612; 3326)

252

69.8%

(63.8; 75.4)

2127

(1909; 2370)

C

Nimenrix

642

97.4%

(95.8; 98.5)

13110

(11939; 14395)

849

91.5%

(89.4; 93.3)

8866

(8011; 9812)

ACWY-PS vaccine

211

96.7%

(93.3; 98.7)

8222

(6807; 9930)

288

92.0%

(88.3; 94.9)

7371

(6297; 8628)

W-135

Nimenrix

639

96.4%

(94.6; 97.7)

8247

(7639; 8903)

860

90.2%

(88.1; 92.1)

5136

(4699; 5614)

ACWY-PS vaccine

216

87.5%

(82.3; 91.6)

2633

(2299; 3014)

283

85.5%

(80.9; 89.4)

2461

(2081; 2911)

Y

Nimenrix

657

93.8%

(91.6; 95.5)

14086

(13168; 15069)

862

87.0%

(84.6; 89.2)

7711

(7100; 8374)

ACWY-PS vaccine

219

78.5%

(72.5; 83.8)

5066

(4463; 5751)

288

78.8%

(73.6; 83.4)

4314

(3782; 4921)

The analysis of immunogenicity was conducted on the ATP cohorts.

(1) Blood sampling performed 1 month post vaccination

VR: vaccine response defined as the proportion of subjects with:

• rSBA titres ≥32 for initially seronegative subjects (i.e., pre-vaccination rSBA titre <8)

• at least a 4-fold increase in rSBA titres from pre- to post-vaccination for initially seropositive subjects (i.e., pre-vaccination rSBA titre ≥8)

* rSBA analysis performed at GSK laboratories

rSBA titres were determined over a period of 10 years in subjects initially vaccinated with one dose of Nimenrix or ACWY-PS at 11 to 17 years of age in Study MenACWY-TT-036. Persistence of rSBA titres was evaluated in two extension studies: MenACWY-TT-043 (up to 5 years) and MenACWY-TT-101 (at 10 years). Study MenACWY-TT-101 also evaluated the response to a single booster dose of Nimenrix administered 10 years following the initial vaccination with Nimenrix or ACWY-PS. Results are shown in Table 13.

Table 13: rSBA* titres following a single dose of Nimenrix (or ACWY-PS) in adolescents aged 11-17 years, persistence up to 10 years, and post-booster administered 10 years following initial vaccination (Studies MenACWY-TT-036/043/101)

Meningo-coccal group

Time point

Nimenrix

ACWY-PS vaccine

N

≥8

(95% CI)

GMT

(95% CI)

N

≥8

(95% CI)

GMT

(95% CI)

A

Month 1(1)

674

100%

(99.5; 100)

5929

(5557; 6324)

224

99.6%

(97.5; 100)

2947

(2612; 3326)

Year 3(2)

449

92.9%

(90.1; 95.1)

448

(381; 527)

150

82.7%

(75.6; 88.4)

206

(147; 288)

Year 5(2)

236

97.5%

(94.5; 99.1)

644

(531; 781)

86

93.0%

(85.4; 97.4)

296

(202; 433)

Year 10(3)

(Pre-booster)

162

85.2%

(78.8; 90.3)

248

(181; 340)

51

80.4%

(66.9; 90.2)

143

(80.5; 253)

(Post-booster)(3,4)

162

100%

(97.7; 100)

3760

(3268; 4326)

51

100%

(93.0; 100)

2956

(2041; 4282)

C

Month 1(1)

673

100%

(99.5; 100)

13110

(11939; 14395)

224

100%

(98.4; 100)

8222

(6808; 9930)

Year 3(2)

449

91.1%

(88.1; 93.6)

371

(309; 446)

150

86.0%

(79.4; 91.1)

390

(262; 580)

Year 5(2)

236

88.6%

(83.8; 92.3)

249

(194; 318)

85

87.1%

(78.0; 93.4)

366

(224; 599)

Year 10(3)

(Pre-booster)

162

90.1%

(84.5; 94.2)

244

(182; 329)

51

82.4%

(69.1; 91.6)

177

(86.1; 365)

(Post-booster)(3,4)

162

100%

(97.7; 100)

8698

(7391 10235)

51

100%

(93.0; 100)

3879

(2715; 5544)

W-135

Month 1(1)

678

99.9%

(99.2; 100)

8247

(7639; 8903)

224

100%

(98.4; 100)

2633

(2299; 3014)

Year 3(2)

449

82.0%

(78.1; 85.4)

338

(268; 426)

150

30.0%

(22.8; 38.0)

16.0

(10.9; 23.6)

Year 5(2)

236

86.0%

(80.9; 90.2)

437

(324; 588)

86

34.9%

(24.9; 45.9)

19.7

(11.8; 32.9)

Year 10(3)

(Pre-booster)

162

71.6%

(64.0; 78.4)

146

(97.6; 217)

51

43.1%

(29.3; 57.8)

16.4

(9.2; 29.4)

(Post-booster)(3,4)

162

100%

(97.7; 100)

11243

(9367; 13496)

51

100%

(93.0; 100)

3674

(2354; 5734)

Y

Month 1(1)

677

100%

(99.5; 100)

14087

(13168; 15069)

224

100%

(98.4; 100)

5066

(4463; 5751)

Year 3(2)

449

93.1%

(90.3; 95.3)

740

(620; 884)

150

58.0%

(49.7; 66.0)

69.6

(44.6; 109)

Year 5(2)

236

96.6%

(93.4; 98.5)

1000

(824; 1214)

86

66.3%

(55.3; 76.1)

125

(71.2; 219)

Year 10(3)

(Pre-booster)

162

90.7%

(85.2; 94.7)

447

(333; 599)

51

49.0%

(34.8; 63.4)

32.9

(17.1; 63.3)

(Post-booster)(3,4)

162

100%

(97.7; 100)

7585

(6748; 8525)

51

98.0%

(89.6; 100)

3296

(1999; 5434)

The analysis of immunogenicity was conducted on the ATP cohort for each time point.

(1) Study MenACWY-TT-036

(2) Study MenACWY-TT-043

(3) Study MenACWY-TT-101

(4) Blood sampling was performed 1 month after a booster dose at Year 10.

*rSBA analysis performed at GSK laboratories for 1 month post primary vaccination samples and at PHE laboratories in UK for the subsequent sampling time points.

hSBA persistence was evaluated up to 5 years after vaccination in adolescents and adults initially vaccinated in Study MenACWY-TT-052 as shown in Table 14 (see section 4.4).

Table 14: hSBA* titres following a single dose of Nimenrix in adolescents and adults aged 11-25 years and persistence up to 5 years following vaccination (Studies MenACWY-TT-052/059)

Meningococcal group

Time point

N

≥8 (95% CI)

GMT (95% CI)

A

Month 1(1)

356

82.0% (77.6; 85.9)

58.7 (48.6; 70.9)

Year 1(2)

350

29.1% (24.4; 34.2)

5.4 (4.5; 6.4)

Year 5(2)

141

48.9% (40.4; 57.5)

8.9 (6.8; 11.8)

C

Month 1(1)

359

96.1% (93.5; 97.9)

532 (424; 668)

Year 1(2)

336

94.9% (92.0; 97.0)

172 (142; 207)

Year 5(2)

140

92.9% (87.3; 96.5)

94.6 (65.9; 136)

W-135

Month 1(1)

334

91.0% (87.4; 93.9)

117 (96.8; 141)

Year 1(2)

327

98.5% (96.5; 99.5)

197 (173; 225)

Year 5(2)

138

87.0% (80.2; 92.1)

103 (76.3; 140)

Y

Month 1(1)

364

95.1% (92.3; 97.0)

246 (208; 291)

Year 1(2)

356

97.8% (95.6; 99.0)

272 (237; 311)

Year 5(2)

142

94.4% (89.2; 97.5)

225 (174; 290)

The analysis of immunogenicity was conducted on the ATP cohort for persistence adapted for each time-point.

(1) Study MenACWY-TT-052

(2) Study MenACWY-TT-059

* hSBA analysis performed at GSK laboratories

rSBA titres were determined over a period of 10 years in subjects initially vaccinated with one dose of Nimenrix or ACWY-PS at 11 to 55 years of age in Study MenACWY-TT-015. Persistence of rSBA titres was evaluated in two extension studies: MenACWY-TT-020 (up to 5 years) and MenACWY-TT-099 (up to 10 years). Study MenACWY-TT-099 also evaluated the response to a single booster dose of Nimenrix administered 10 years following the initial vaccination with Nimenrix or ACWY-PS. Results are shown in Table 15.

Table 15: rSBA* titres following a single dose of Nimenrix (or ACWY-PS) in adolescents and adults aged 11-55 years, persistence up to 10 years, and post-booster administered 10 years following initial vaccination (Studies MenACWY-TT-015/020/099)

Meningo-coccal group

Time point

Nimenrix

ACWY-PS vaccine

N

≥8

(95% CI)

GMT

(95% CI)

N

≥8

(95% CI)

GMT

(95% CI)

A

Month 1(1)

323

100%

(98.9; 100)

4945

(4452, 5493)

112

100%

(96.8, 100)

2190

(1858, 2582)

Year 4(2)

43

95.3%

(84.2; 99.4)

365

(226; 590)

17

76.5%

(50.1; 93.2)

104

(31.0; 351)

Year 5(2)

51

84.3%

(71.4; 93.0)

190

(108; 335)

19

57.9%

(33.5; 79.7)

37.0

(12.6; 109)

Year 10(3)

(Pre-booster)

155

78.1%

(70.7; 84.3)

154

(108; 219)

52

71.2%

(56.9; 82.9)

75.1

(41.4; 136)

(Post-booster)(3,4)

155

100%

(97.6; 100)

4060

(3384; 4870)

52

100%

(93.2; 100)

3585

(2751; 4672)

C

Month 1(1)

341

99.7%

(98.4; 100)

10074

(8700, 11665)

114

100%

(96.8; 100)

6546

(5048; 8488)

Year 4(2)

43

76.7%

(61.4; 88.2)

126

(61.6; 258)

17

41.2%

(18.4; 67.1)

16.7

(5.7; 48.7)

Year 5(2)

51

72.5%

(58.3; 84.1)

78.5

(41.8; 147)

18

38.9%

(17.3; 64.3)

17.3

(6.0; 49.7)

Year 10(3)

(Pre-booster)

154

90.9%

(85.2; 94.9)

193

(141; 264)

52

88.5%

(76.6; 95.6)

212

(110; 412)

(Post-booster)(3,4)

155

100%

(97.6; 100)

13824

(10840; 17629)

52

98.1%

(89.7; 100)

3444

(1999; 5936)

W-135

Month 1(1)

340

99.7%

(98.4; 100)

8577

(7615; 9660)

114

100%

(96.8; 100)

2970

(2439; 3615)

Year 4(2)

43

90.7%

(77.9; 97.4)

240

(128; 450)

17

17.6%

(3.8; 43.4)

8.3

(3.6; 19.5)

Year 5(2)

51

86.3%

(73.7; 94.3)

282

(146; 543)

19

31.6%

(12.6; 56.6)

15.4

(5.7; 41.9)

Year 10(3)

(Pre-booster)

154

71.4%

(63.6; 78.4)

166

(107; 258)

52

21.2%

(11.1; 34.7)

10.9

(6.1; 19.3)

(Post-booster)(3,4)

155

100%

(97.6; 100)

23431

(17351; 31641)

52

98.1%

(89.7; 100)

5793

3586; 9357)

Y

Month 1(1)

340

100%

(98.9; 100)

10315

(9317; 11420)

114

100%

(96.8; 100)

4574

(3864; 5414)

Year 4(2)

43

86.0%

(72.1; 94.7)

443

(230; 853)

17

47.1%

(23.0; 72.2)

30.7

(9.0; 105)

Year 5(2)

51

92.2%

(81.1; 97.8)

770

(439; 1351)

19

63.2%

(38.4; 83.7)

74.1

(21.9; 250)

Year 10(3)

(Pre-booster)

154

86.4%

(79.9; 91.4)

364

(255; 519)

52

61.5%

(47.0; 74.7)

56.0

(28.8; 109)

(Post-booster)(3,4)

155

100%

(97.6; 100)

8958

(7602; 10558)

52

100%

(93.2; 100)

5138

(3528; 7482)

The analysis of immunogenicity was conducted on the ATP cohorts for 1 month and 5 years post vaccination and the booster ATP cohort.

(1) Study MenACWY-TT-015

(2) Study MenACWY-TT-020

(3) Study MenACWY-TT-099

(4) Blood sampling was performed 1 month after a booster dose at Year 10.

* rSBA analysis performed at GSK laboratories for 1 month post primary vaccination samples and at PHE laboratories in UK for the subsequent sampling time points.

In a separate study (MenACWY-TT-085) a single dose of Nimenrix was administered to 194 Lebanese adults aged 56 years and older (including 133 aged 56-65 years and 61 aged >65 years). The percentage of subjects with rSBA titres (measured at GSK's laboratories) ≥128 before vaccination ranged from 45% (group C) to 62% (group Y). Overall, at 1 month post-vaccination the percentage of vaccines with rSBA titres ≥128 ranged from 93% (group C) to 97% (group Y). In the subgroup aged >65 years the percentage of vaccines with rSBA titres ≥128 at 1 month post-vaccination ranged from 90% (group A) to 97% (group Y).

Booster response for subjects previously vaccinated with a conjugate meningococcal vaccine against Neisseria meningitidis

Nimenrix booster vaccination in subjects previously primed with a monovalent (MenC-CRM) or a quadrivalent conjugate meningococcal vaccine (MenACWY-TT) was studied in subjects from 12 months of age onwards who received a booster vaccination. Robust anamnestic responses to the antigen(s) in the priming vaccine were observed (see Tables 6, 7, 11, 13, and 15).

Response to Nimenrix in subjects previously vaccinated with a plain polysaccharide vaccine against Neisseria meningitidis

In Study MenACWY-TT-021 conducted in subjects aged 4.5-34 years, the immunogenicity of Nimenrix administered between 30 and 42 months after vaccination with a ACWY-PS vaccine was compared to the immunogenicity of Nimenrix administered to age-matched subjects who had not been vaccinated with any meningococcal vaccine in the preceding 10 years. An immune response (rSBA titre ≥8) was observed against all four meningococcal groups in all subjects regardless of the meningococcal vaccine history. The rSBA GMTs were significantly lower in the subjects who had received a dose of ACWY-PS vaccine 30-42 months prior to Nimenrix, however 100% of subjects achieved rSBA titres ≥8 for all four meningococcal groups (A, C, W-135, Y) (see section 4.4).

Children (2-17 years) with anatomical or functional asplenia

Study MenACWY-TT-084 compared immune responses to two doses of Nimenrix given 2 months apart between 43 subjects aged 2-17 years with anatomic or functional asplenia subjects and 43 age-matched subjects with normal splenic function. One month after the first vaccine dose and 1 month after the second dose similar percentages of subjects in the two groups had rSBA titres ≥8 and ≥128 and hSBA titres ≥4 and ≥8.

5.2 Pharmacokinetic properties

Not applicable.

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on local tolerance, acute toxicity, repeated dose toxicity, developmental/reproductive toxicity and fertility studies.

6. Pharmaceutical particulars
6.1 List of excipients

Powder:

Sucrose

Trometamol

Solvent:

Sodium chloride

Water for injections

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

4 years

After reconstitution:

After reconstitution, the vaccine should be used promptly. Although delay is not recommended, stability has been demonstrated for 8 hours at 30°C after reconstitution. If not used within 8 hours, do not administer the vaccine.

6.4 Special precautions for storage

Store in a refrigerator (2°C – 8°C).

Do not freeze.

Store in the original package in order to protect from light.

For storage conditions after reconstitution of the medicinal product, see section 6.3.

6.5 Nature and contents of container

Powder in a vial (type I glass) with a stopper (butyl rubber) and solvent in a pre-filled syringe with a stopper (butyl rubber).

Pack sizes of 1 and 10 with or without needles.

Not all pack sizes may be marketed.

Powder in a vial (type I glass) with a stopper (butyl rubber) and solvent in a vial (type I glass) with a stopper (butyl rubber).

Pack size of 50.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

Instructions for reconstitution of the vaccine with the solvent presented in pre-filled syringe

Nimenrix must be reconstituted by adding the entire content of the pre-filled syringe of solvent to the vial containing the powder.

To attach the needle to the syringe, refer to the below picture. However, the syringe provided with Nimenrix might be slightly different (without screw thread) than the syringe described in the picture. In that case, the needle should be attached without screwing.

1. Holding the syringe barrel in one hand (avoid holding the syringe plunger), unscrew the syringe cap by twisting it anticlockwise

 

 

 

 

2. To attach the needle to the syringe, twist the needle clockwise into the syringe until you feel it lock (See picture).

3. Remove the needle protector, which on occasion can be a little stiff.

4. Add the solvent to the powder. After the addition of the solvent to the powder, the mixture should be well shaken until the powder is completely dissolved in the solvent.

The reconstituted vaccine is a clear colourless solution.

The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or variation of physical aspect prior to administration. In the event of either being observed, discard the vaccine.

After reconstitution, the vaccine should be used promptly.

A new needle should be used to administer the vaccine.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Instructions for reconstitution of the vaccine with the solvent presented in vials

Nimenrix must be reconstituted by adding the entire contents of the solvent vial to the vial containing the powder.

1. Withdraw the entire contents of the solvent vial and add the solvent to the powder vial.

2. The mixture should be well shaken until the powder is completely dissolved in the solvent.

The reconstituted vaccine is a clear colourless solution.

The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or variation of physical aspect prior to administration. In the event of either being observed, discard the vaccine.

After reconstitution, the vaccine should be used promptly.

A new needle should be used to administer the vaccine.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. Marketing authorisation holder

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

1050 Bruxelles

Belgium

8. Marketing authorisation number(s)

pre-filled syringe

EU/1/12/767/001

EU/1/12/767/002

EU/1/12/767/003

EU/1/12/767/004

vial

EU/1/12/767/008

9. Date of first authorisation/renewal of the authorisation

Date of first authorisation: 20 April 2012

Date of latest renewal: 16 February 2017

10. Date of revision of the text

01/2020

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu

Ref: NI 14_0